CRO

FDA clarifies its rules on CMO interruptions; Almac buys new equipment; ERT enjoys revenue growth;

> Anxious to steer clear of future drug shortages, the FDA is warning sole-source suppliers of drugs that they still have to notify the agency of any manufacturing interruptions, even if they've outsourced the manufacturing process to a CMO. The agency has been grappling with a public relations nightmare as patients and physicians complain of a growing problem finding needed meds, including some crucial cancer drugs. Report

> Almac has acquired two new pieces of encapsulation equipment. Release

> ERT's new CEO says the decision to stop turning away business has helped push revenue growth. Story

> Charles River Laboratories is licensing EMD Millipore's TrueSpike technology to clean up virus preparations used to validate biomanufacturing process virus clearance. Release